A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03447249 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

385

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-659/TEZ/IVA
DRUG: IVA
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated